Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
STAT+: Pharmalittle: We’re Reading About the FDA Speeding up Trials, a Supreme Court Hearing on ‘Skinny Labels,’ and More
The FDA announced a pilot program that will review real‑time data from AstraZeneca and Amgen cancer trials using a platform built by Paradigm Health, aiming to speed regulatory feedback. The agency also opened a public comment period on a separate AI‑driven pilot to enhance safety monitoring and patient recruitment. Meanwhile, Pfizer settled patent disputes with three generic manufacturers, extending protection for its heart drug Vyndamax until June 2031 and postponing cheaper copies. The settlement lets Pfizer expect steady sales through 2031 after previously forecasting a revenue dip in 2029.
Apple Vision Pro Powers First VR-Assisted Surgery, Heralding Medical Future
‘Safer, smarter, and more connected’: Apple’s Vision Pro used in world-first VR-assisted surgery, and it could be the future of medicine https://www.techradar.com/computing/virtual-reality-augmented-reality/safer-smarter-and-more-connected-apples-vision-pro-used-in-world-first-vr-assisted-surgery-and-it-could-be-the-future-of-medicine
Early Specialist Care Could Prevent 10,000 UK Miscarriages Annually, Study Shows
Researchers from Tommy’s National Centre for Miscarriage Research and Birmingham Women’s Hospital report that a graded model of specialist care after a first miscarriage could avert roughly 10,000 future losses annually. The findings, based on 406 women, show a 4%...
On the Move: Penn State Health Names Royer PR Chief
Penn State Health announced the appointment of Dara Royer as senior vice president and chief marketing and communications officer, effective June 29. Royer arrives from Syracuse University after senior roles at Mercy Corps and St. Jude Children’s Research Hospital. At the...
Expansion Planned for Assisted Living Facility at 2820 Sycamore Ave. In Glendale
Episcopal Communities & Services plans to expand its Twelve Oaks assisted‑living campus at 2820 Sycamore Avenue in Glendale. The developer will demolish 12 existing structures that house 60 residents and replace them with a three‑story, 92,240‑square‑foot building offering 104 senior beds....
Medtronic Confirms Cyberattack as ShinyHunters Claims Theft of 9 Million Medical Records
Medtronic disclosed a cyberattack on its corporate IT systems after the ShinyHunters ransomware group claimed to have stolen roughly 9 million medical records. The company said patient safety and product operations were unaffected, but the breach raises significant data‑privacy questions for...
Insilico Medicine Secures IND for AI-Designed Rentosertib Inhalation, First Direct‑to‑Lung Trial
Insilico Medicine announced IND clearance from China's CDE for its AI‑designed Rentosertib inhalation solution, marking the 13th AI‑driven program to reach clinical testing and the first to use a direct‑to‑lung delivery route. The Phase I study will enroll about 80...
Pfizer Settles with Generic Drugmakers to Protect Blockbuster Drug Until 2031
Pfizer reached settlements with three generic manufacturers—Dexcel Pharma, Hikma Pharmaceuticals and Cipla—to postpone the launch of off‑patent copies of its heart‑disease drug Vyndamax until mid‑2031. The agreement stabilizes U.S. sales, which hit $3.8 billion in 2025, and averts the steep revenue...
“Technology Needs to Enable Neighbourhood Working, Not Constrain It”
Neighbourhood care aims to integrate acute, primary, community and mental health services, but digital interoperability gaps hinder its rollout. Clinicians face duplicate data entry because systems across organisations don’t share updates. Harris Health Alliance is piloting the conneQT Toolbar, an...
Talkiatry and New York Cancer & Blood Specialists Partner to Expand Mental Health Access for Oncology Patients
New York Cancer & Blood Specialists (NYCBS) has partnered with telepsychiatry provider Talkiatry to embed psychiatric care into its oncology network. The collaboration will roll out across more than 30 NYCBS locations, giving patients access to over 300 board‑certified psychiatrists...
Surgeries Are Moving to ASCs. Distalmotion Wants Its Robot to Drive the Shift.
Distalmotion, a Swiss medtech spinoff, is targeting the rapid migration of low‑risk surgeries to ambulatory surgery centers (ASCs) with its Dexter robotic system. The robot, cleared by the FDA for inguinal hernia, gallbladder removal and hysterectomy, offers a compact 125‑sq‑ft...
Virtual Nursing Staff May Help Save Cardiology Departments From Burnout
Cardiology departments are facing rising physician burnout as administrative duties eclipse patient care, prompting health systems to seek innovative staffing models. MedStar Health and Abundant Venture Partners launched Auxira Health, a startup that supplies remote clinical pods of advanced practice...
Advancing Healthcare Innovation with the Mayo Clinic–ASU Health Care Accelerator and Industry
The Mayo Clinic and Arizona State University have launched the Mayo Clinic–ASU Health Care Accelerator, a program that moves early‑stage healthcare technologies toward clinical adoption. Intel’s General Manager Alex Flores discussed the accelerator on HIMSSCast, highlighting how sustained industry engagement,...
When ADCs Meet Targeted Protein Degraders: The Emerging Field of Degrader-Antibody Conjugates
The biotech sector is exploring degrader‑antibody conjugates (DACs), a hybrid that merges antibody‑drug conjugate targeting with catalytic protein‑degradation payloads. C4 Therapeutics has expanded its partnership with Roche to co‑develop two undisclosed oncology DAC programs, while Orum Therapeutics secured $100 million to...
GSK’s Shingrix Strategy Shift Drives Sales Beat Even as Vaccines Slow
GSK’s shingles vaccine Shingrix posted a 20% sales jump to $1.4 billion in Q1 2025, beating analysts’ $1.15 billion forecast. The boost came largely from a 51% year‑on‑year surge in Europe and a 12% rise in the United States after the company...
Trump’s Medicaid Fraud Crackdown May Sound Sensible, but It Could Harm Americans Who Require Long-Term Care
CMS Administrator Mehmet Oz announced a nationwide push for states to revalidate Medicaid providers deemed high‑risk, targeting home‑and‑community‑based services. The directive follows Trump‑era enforcement actions that have already threatened to withhold funds from states such as Minnesota, New York, California and...
Cigna's "Transparency Report" Is Just a PR Stunt
After UnitedHealthcare CEO Brian Thompson was killed, a wave of patient stories forced insurers to confront public anger. Cigna responded with a multi‑year reform agenda and released a Customer Transparency Report claiming a 15% cut in prior‑authorization volume by removing...
AstraZeneca Makes Surprise U-Turn with £300m Pharma Investment in UK
AstraZeneca announced a surprise £300 million (≈$381 million) investment in the UK, unfreezing a £200 million (≈$254 million) Cambridge expansion and allocating £100 million (≈$127 million) to a new "lab of the future" in Macclesfield. The move follows a pause last year after the company expressed...
Psychedelics Go Mainstream: Medicine, Mania Or Both?
Psychedelics are re‑emerging as a potential breakthrough in behavioral health, spurred by loosening regulations and a Trump‑issued executive order that accelerated research. Early clinical data suggest benefits for depression, PTSD and other conditions, prompting biotech stocks to rally after FDA...
Many Peers Sought to Amend This Badly Drafted Bill
The Terminally Ill Adults (End of Life) Bill, the longest Private Members’ Bill ever introduced in the House of Lords, ran out of time after a rare two‑day second reading. Critics, including the Constitution Committee, flagged serious drafting flaws, and...
Center for Connected Medicine at UPMC Finds EHR Integration Gap Is Defining Hurdle for Precision Medicine Scale
The Center for Connected Medicine at UPMC, together with KLAS Research and the Institute for Precision Medicine, found that 75 % of U.S. health systems now have formal precision‑medicine programs, up from 31 % in 2020, and that deep EHR integration of...
Amgen, AZ Will Pilot FDA's Real-Time Clinical Trial Plan
The FDA unveiled a plan to receive clinical‑trial data in real time, aiming to accelerate drug development. AstraZeneca and Amgen have agreed to pilot the model with two studies that will stream endpoints and safety signals to regulators as they...
Saudia Cargo Announces Critical Medicine Logistics Initiative
Saudia Cargo has launched a joint initiative with the Saudi Food and Drug Authority to reinforce pharmaceutical and medical supply chains across the Kingdom. The program offers upgraded handling facilities and shipping cost reductions of up to 50%, aiming to...
Winning over Medtech Investors in the Age of AI
MedTech founders are feeling squeezed by AI hype, which dominates investor dialogue. Dr. Anne Blackwood argues that investors actually value clear clinical evidence, market need, and experienced teams more than flashy AI claims. She outlines five practical steps—lead with the...
Robotics
Ekso Bionics' Ekso GT™ exoskeleton became the first FDA‑cleared wearable robot for stroke rehabilitation in May 2016. The device enables individuals with lower‑limb paralysis to stand and walk during therapy sessions. It also secured clearance for certain spinal‑cord‑injury patients, marking a...
Revolution’s on a Pancreatic Cancer Winning Streak. What Comes Next for the Biotech?
Revolution Medicines announced that its oral RAS(ON) inhibitor daraxonrasib nearly doubled overall survival in previously treated metastatic pancreatic cancer, while its second candidate zoldonrasib showed tumor shrinkage in over half of KRAS‑driven lung cancer patients. The breakthrough data sent the...
Debbie East-Nuttall | Meet the Speakers: Med-Tech Expo 2026
Debbie East‑Nuttall, Head of Medical Business Development at Kiwa, will present at Med‑Tech Expo 2026 on simplifying ISO 13485 compliance and setting realistic market‑entry timelines. Leveraging 35 years of industry experience, she will expose common pitfalls that delay approvals. The session,...
Check Your Hearing Early with Dr. Rufina Yakubov
What a great healer, Doctor Rufina Yakubov fifthavenuehearing an audiologist who helps many of us participate and bask in the aural landscape that is life. Check your hearing. Please. Many put this off and begin to do real neurological...
The 20 Enterprise AI Drug Discovery & Life Sciences CEOs You Need to Know in 2026
The AI Insider has compiled a roster of the 20 most influential CEOs steering enterprise AI drug discovery and life‑sciences firms in 2026. The list showcases companies that are compressing decade‑long development cycles into months through generative protein design, AI‑optimized...
Drug Trials Snapshot: DAXXIFY
Revance Therapeutics’ DAXXIFY, a daxibotulinumtoxin A formulation, received FDA approval on September 7 2022 for temporary reduction of moderate to severe glabellar lines. Approval was based on two randomized, double‑blind, placebo‑controlled trials (GL‑1 and GL‑2) that enrolled 609 adults across the United States...
HUTCHMED Reports NMPA’s NDA Acceptance Under Priority Review for Sovleplenib to Treat wAIHA
HUTCHMED’s oral JAK2 inhibitor sovleplenib has received NDA acceptance and priority review from China’s National Medical Products Administration for warm‑antibody autoimmune hemolytic anemia (wAIHA). The submission is backed by Phase II/III data showing a 43.8% overall response rate versus 0%...
Investigate Who Profits From Overprescribing SSRIs, Like Opioids
We should find out who's really responsible for doctorss prescribing so many SSRIs We have to follow the money Just like they did with the opioids epidemic
Meet the Brand New Excuse for Medical Failures; It’s a Doozy
Google AI released research indicating roughly 10% of patients may not respond to GLP‑1 weight‑loss drugs because of specific genetic variations. The finding is framed as a scientific explanation for drug inefficacy, suggesting that patient genetics, not the medication, drive...
Drug Trials Snapshots: VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK
Phathom Pharmaceuticals’ VOQUEZNA TRIPLE PAK (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA DUAL PAK (vonoprazan, amoxicillin) received FDA approval for adult Helicobacter pylori infection based on a 992‑patient trial across six countries. In the modified intent‑to‑treat population, the triple regimen eradicated the...
GSK CEO Says Team Reorg Could Be in the Cards Pending Upcoming Phase 3 Readouts
GlaxoSmithKline (GSK) is banking on a slate of late‑stage Phase 3 trials slated for 2024, spanning oncology drugs and next‑generation vaccines. CEO Luke Miels warned on the first‑quarter earnings call that a series of missed readouts could trigger a reshuffle of...
Federal Employees Health Benefits Program: Additional Actions Needed to Address Significant Risks in Verifying Provider Eligibility
The Government Accountability Office found that OPM’s control activities allow ineligible providers to submit claims to the Federal Employees Health Benefits (FEHB) program. GAO identified roughly 400 claims from deceased providers and more than 2,000 claims from providers excluded from...
Drug Trials Snapshot: OPDUALAG
OPDUALAG, a fixed‑dose combo of nivolumab and relatlimab, received FDA approval in March 2022 for adults and adolescents with unresectable or metastatic melanoma. The pivotal trial enrolled 714 patients and showed a median progression‑free survival of 10.1 months versus 4.6...
Drug Trials Snapshots: VONJO
VONJO (pacritinib) received FDA accelerated approval on Feb. 28, 2022 for adult myelofibrosis patients with platelet counts ≤50,000/µL. The decision rests on a single trial that enrolled 63 low‑platelet patients, of whom 31 received VONJO and 32 received best available therapy. In...
Drug Trials Snapshot: PYRUKYND
AGIOS Pharmaceuticals’ mitapivat, marketed as PYRUKYND, received FDA approval in February 2022 for treating hemolytic anemia caused by pyruvate kinase deficiency. In pivotal trials, 40% of non‑transfused adults achieved a ≥1.5 g/dL hemoglobin increase versus none on placebo, while 33% of...
Six-Step Playbook for Risk‑Stratified Lipid‑Lowering Therapy
Reducing cardiovascular risk: a playbook for lipid-lowering pharmacotherapy Risk-stratified targets and a six-step playbook for choosing, combining, and escalating lipid-lowering therapy https://t.co/PcIQNxmivX https://t.co/SzTN9ZAD85
Drug Trials Snapshots: ENJAYMO
ENJAYMO (sutimlimab‑jome) received FDA approval in February 2022 as the first therapy to reduce red‑blood‑cell transfusions in adults with cold agglutinin disease (CAD). Approval was based on a single open‑label, single‑arm trial (CARDINAL) that enrolled 24 patients across eight countries. After...
Rethinking Prosthetics: The Challenge of Four Legged Patients
Animal prosthetics and orthotics remain a fragmented niche, demanding design approaches distinct from human care. Differences in limb biomechanics, lack of footwear, and variable ground‑reaction forces make 3D‑printed solutions far more complex to engineer. Specialists like Danielle Robins act as advisors,...
Drug Trials Snapshots: VABYSMO
VABYSMO (faricimab‑svoa), approved in January 2022, was evaluated in four pivotal trials involving 2,591 patients with neovascular age‑related macular degeneration (nAMD) and diabetic macular edema (DME). The drug was administered monthly for four doses before transitioning to a personalized schedule based...
An Uncomfortable Truth: Healthcare Is Both a Protector of Health and a Contributor to One of Its Greatest Threats
Healthcare contributes roughly 5% of global greenhouse‑gas emissions, placing the sector among the world’s top five emitters. Up to 70% of that footprint originates from the supply chain—pharmaceuticals, devices, and single‑use items—while hospitals themselves account for about 30% of emissions...
Drug Trials Snapshot: CIBINQO
Pfizer's oral JAK inhibitor CIBINQO (abrocitinib) received FDA approval in January 2022 for adults with refractory moderate‑to‑severe atopic dermatitis. The approval rests on three phase‑3 trials involving 1,615 patients across 18 countries, which demonstrated robust skin‑clearance outcomes at week 12, especially with...
Piramal Pharma Eyes Strong Earnings Growth over Next 2–3 Years
Piramal Pharma aims for early‑to‑mid‑teens revenue growth over the next two to three years, driven by rising demand for complex drugs such as antibody‑drug conjugates (ADCs). The Indian CDMO relies on contract manufacturing for 55% of its revenue, which fell...
China Unveils 2026 Dietary Guidelines for Stroke, Osteoporosis and Sarcopenia
The National Health Commission of China has issued three 2026 adult dietary guidelines targeting stroke, osteoporosis and sarcopenia. The guidelines merge modern nutrition science with traditional Chinese food‑medicine, offering region‑specific meal plans and practical recommendations for millions of Chinese citizens.
Envisioning More Inclusive Gender-Affirming Care Amid Widespread Attacks
The Trump administration’s anti‑trans agenda has prompted FDA warnings to binder manufacturers, threatened Medicaid and Medicare funding, and forced hospitals to halt gender‑affirming programs for minors. These actions coincide with a 72% surge in youth suicide rates in states that...
Drug Trials Snapshot: IMAAVY
IMAAVY (nipocalimab‑aahu) received FDA approval on April 29, 2025 for generalized myasthenia gravis in patients 12 years and older with AChR or MuSK antibodies. In a pivotal 24‑week Phase III trial of 196 adults, the drug achieved a statistically significant 1.5‑point improvement...
The $5B Test: Why Healthcare Compliance Programs Keep Failing the Same Way
In fiscal year 2025 the U.S. government recovered a record $6.8 billion under the False Claims Act, with $5.7 billion stemming from healthcare fraud. Despite mandatory compliance programs, many are built to pass audits rather than change behavior, leading to a surge...